NovaBay Pharmaceuticals Strengthens Global Aganocide Patent Estate With Seven New Patents

NovaBay Pharmaceuticals, Inc. (NYSE: NBY), a clinical-stage biotechnology company developing first-in-class "non-antibiotic anti-infective" products for the treatment and prevention of topical infections, today announced three new composition of matter patent issuances in Australia, New Zealand and Mexico and four Notices of Allowance in Canada, Japan, South Africa and Mexico on its proprietary Aganocide compounds which includes its lead compound, NVC-422.

(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.